Status:
TERMINATED
18F-Fluoromisonidazole and Fludeoxyglucose F 18 PET/CT Patients With Soft Tissue Sarcoma
Lead Sponsor:
National Cancer Institute (NCI)
Conditions:
Recurrent Adult Soft Tissue Sarcoma
Stage I Adult Soft Tissue Sarcoma
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This phase II trial is studying 18F-fluoromisonidazole and fludeoxyglucose F 18 PET/CT scans to see how well they work in assessing oxygen in tumor tissue of patients with soft tissue sarcoma undergoi...
Detailed Description
PRIMARY OBJECTIVES: I. Evaluate the potential of 18F-fluoromisonidazole (\[18F\] FMISO) as a non-invasive indicator of tissue hypoxia to provide tumor-imaging data that correlates with tissue markers...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Histologically confirmed intermediate- or high-grade soft tissue sarcoma
- Biopsy proven or highly suspicious primary or recurrent disease
- Tumor size ≥ 2 cm
- Scheduled to undergo neoadjuvant chemotherapy with or without radiotherapy
- Life expectancy ≥ 12 months
- Negative pregnancy test
- Willing to undergo PET scanning
- Willing to undergo possible urinary bladder catheterization (for patients with pelvic or proximal thigh tumors)
- Able to lie on the imaging table for up to 1.5 hours
- Weight ≤ 400 lbs
- Not pregnant
Exclusion
Key Trial Info
Start Date :
February 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2013
Estimated Enrollment :
8 Patients enrolled
Trial Details
Trial ID
NCT01169350
Start Date
February 1 2010
End Date
August 1 2013
Last Update
November 17 2017
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Seattle Cancer Care Alliance
Seattle, Washington, United States, 98109-1023
2
University of Washington Medical Center
Seattle, Washington, United States, 98195